Heterogeneity of the cardiovascular response to hemofiltration  by Henderson, Lee W.
Kidney International, Vol. 29 (1986), pp. 901—907
Heterogeneity of the cardiovascular response to hemofiltration
LEE W. HENDERSON
Department of Medicine, Veterans Administration Medical Center, San Diego, California; and Department of Medicine, University of
California, San Diego, La Jolla, California, USA
Heterogeneity of the cardiovascular response to hemofiltratlon.
Twenty—one stable maintenance hemodialysis patients were studied in
a crossover format with hemofiltration to determine whether the lower
incidence of symptomatic hypotension noted with hemofiltration could
be correlated with changes in barorefiex function as tested using the
cold pressor test and amyl nitrite inhalation study. Baroreflex function
remained abnormal and unchanged in all patients in the face of a
reduced incidence of symptomatic hypotension. Subdivision of the
patients into frequent (> 1 episode/treatment) and infrequent (< I
episode/treatment) reactors during the hemodialysis control period
resulted in the infrequent reactors, showing a significant increase in
episodes of symptomatic hypotensionlhemofiltration treatment where a
significant reduction was noted with the frequent reactors. No clear
correlation could be made between the incidence of symptomatic
hypotension and the pre- to post-treatment change in body temperature.
The presence of pretreatment hypertension, another previously identi-
fied correlate of symptomatic hypotension with hemodialysis, also
could not be corroborated. Further, changes from baseline predialysis
values in mean arterial pressure noted with hemofiltration could not be
correlated with a changed incidence of symptomatic hypotension. We
conclude that previously identified correlates of symptomatic hypoten-
sion noted in the hemodialysis setting may be dissociated during
treatment with hemofiltration and that there is a heterogeneous patient
response to this treatment. These data suggest that there are additional,
as yet undetermined, pathophysiologic events that underly the symp-
tomatic hypotension of artificial kidney treatment.
A significant fall in blood pressure accompanied by a variety
of symptoms occurs in approximately 20 to 30% of all hemodi-
alysis treatments in patients with stable end stage renal failure
[1, 2, 3]. Hemofiltration for reasons yet to be explained is
associated with a lower incidence (approximately 10%) of this
morbid event [1, 3, 4]. Autonomic neuropathy is demonstrably
present in upwards of 50% of patients with end stage renal
disease [5, 6] and has been correlated with both the occurrence
of symptomatic hypotension during hemodialysis and to hyper-
tension between treatments [7]. Recent work suggests that a fall
in body temperature induced by hemofiltration correlates with
improved cardiovascular stability during treatment [8].
The present work examines baroreflex arc function and blood
pressure as well as changes in body temperature and weight in
patients moving from maintenance hemodialysis to mainte-
nance hemofiltration, to determine whether there is a correla-
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tion between the reduced incidence of symptomatic hypoten-
sion, and these previously identified correlates.
Methods
Twenty-one patients (20 m, 1 1) with end stage renal failure
being maintained on a Monday, Wednesday, Friday, four—hour
hemodialysis schedule, using cellulosic membrane (cuprophane
for 17, cellophane for 4) dialyzers were selected for study. They
were free of identifiable systemic disease, specifically: infec-
tion, diabetes mellitus, lupus erythematosis, periarteritis and
amyloidosis. All were taken from the hemodialysis unit of the
VAMC San Diego and were considered to be stable mainte-
nance dialysis patients. Informed consent was a requirement for
participation in the study. The average time on dialysis was 24
7 mo. The mean age of the study group was 55 3 yrs (31 to
71 year range). Six patients were normotensive and 15 had
hypertension, defined as a pretreatment mean arterial pressure
> 105 mmHg, determined when the patient was considered to
be at or below his "dry weight." All antihypertensive medica-
tion was discontinued two weeks prior to the start of the study
protocol and was withheld for the duration of the study.
Hemodialysis was carried out using an acetate bath. Patients
were then switched to hemofiltration for twelve weeks using
replacement solution that contained a higher acetate and so-
dium concentration than that used for hemodialysis (Table 1).
Hemofiltration was carried out with predilution using 0.55 M
XP-50 hollow fiber polysulfone membrane (Grace Amicon D-30
hemofilter, Amicon, Lexington, Massachusetts, USA). Fifty to
70 liters of diluting fluid was used per treatment.
Seated blood pressure was obtained using an arm cuff by the
nurse just prior to initiating treatment and hourly thereafter.
Treatment for episodes of SH consisted of intravenously ad-
ministered hypertonic saline (50 mEq in 12 cc) mannitol (25 g in
25 cc) or isotonic saline (100 to 300 cc) singly or rarely in
combination. During treatment, symptomatic hypotension was
considered to be present when the nurse treated the patient for
symptoms and/or the measured blood pressure was at or below
100/70 mmHg or was 20/20 mmHg below the last hourly routine
recorded blood pressure. Beam balance body wts were ob-
tained pre- and post-treatment.
The amyl nitrite inhalation study was conducted on the day
following dialysis. Blood pressure was monitored using a
brachial artery catheter and a pressure transducer (Hewlett-
Packard Model 1280C, Elkhart, Indiana, USA) connected to a
two channel strip chart recorder (Hewlett-Packard 7702B).
Lead V-2 of the EKG was simultaneously recorded at a paper
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Dialysis Bath Diluting Fluid
Sodium 133 140
Potassium 2.0 2,0
Calcium 3.5 3.5
Magnesium 1.5 1.5
Chloride 105 106
Acetate 37 41
Glucose 100 (mg%) 100 (mg%)
speed of 25 mm/sec. Barorefiex sensitivity obtained when blood
pressure was below baseline was evaluated by recording the
increase in heart rate in response to a fall in arterial pressure
induced by amyl nitrite inhalation [91. Changes in mean arterial
pressure (MAP) and pulse interval were recorded continuously
following amyl nitrite inhalation. Baroreflex sensitivity was
calculated as the quotient of the induced pulse interval change
in the EKG on the succeeding beat divided by the change in
MAP on the preceding beat, utilizing cardiac cycles at baseline
and during development of maximal amy! nitrite induced hypo-
tension. Results are expressed as units of msec/mmHg. The
cold pressor test was conducted by having the subject place his
hand (contralateral to the site of vascular access) in ice water
for one minute during continuous monitoring of the EKG and
intraarterial pressure. Both the change in R—R interval (msec)
and maximum change in MAP were recorded. Temperature was
measured just before and at the conclusion of each artificial
kidney treatment using a sublingual thermister (IVAC Model
811).
Pretreatment levels in plasma were obtained for sodium,
blood urea nitrogen and plasma dopamine B-hydroxylase
(DBH) activity from the seated patient without tourniquet
through the fistula needle between 7:45 and 8:00 a.m. prior to
initiating dialysis. The spectrophotometric method of Negatsu
and Udenfried as previously reported by our group [10] was
used to measure DBH (International units/liter). Three mea-
surements were performed serially: prior to each of three
treatments, at the conclusion of the dialysis study period, and at
the conclusion of hemofiltration. Values were averaged for each
patient to obtain a single study period value for statistical
analysis.
Paired and non-paired t tests were used as appropriate for
comparisons of the same patient with different treatment mo-
dalities, or between different patient groups on the same mo-
dality. Analysis of variance was used to determine the signifi-
cance of differences in the monthly study periods for a given
treatment modality.
Results
Figure 1 plots the percent of treatments in which one or more
episodes of symptomatic hypotension occurred with
hemodialysis and hemofiltration in the group of 21 patients
studied. While values for the first and second month (F-i 54
6%, F-2 = 44 6%, mean 1 suM) show lower values than
for the 343 control observations on hemodialysis (58 8%),
they do not achieve statistical significance at the P < .05 level
until the third month (F-3 = 34 6%). With the first month back
on hemodialysis there is a prompt return to the control value
Number of treatments with SH
x 100 in 21 patientsNumber nf treatments
(Mean 1 SFM(
N 343 315 269 248 289 255 304
* Pc 0.05 vs. 0-0
Study period
Fig. 1. Percent incidence of symptomatic hypotension (SH) in 21
patients is shown. Control observations on hemodialysis (D-0) are
compared with three months of hemofiltration treatment (F-i, F-2,
and again with three months of post hemofiltration hemodialysis (D-1,
D-2, D-3). N represents the number of treatments observed in each
study period.
and this frequency is maintained until the end of the study.
Examination of the number of episodes of symptomatic hypo-
tension per study period (not shown), which takes into account
multiple episodes of symptomatic hypotension during a single
treatment rather than the number of treatments, in which one or
more episodes of symptomatic hypotension occurred results in
similar findings, except that statistical significance is present in
the F-2 study period in additon to F-3.
Figure 2 divides the patient study group using the criterion of
hypertension. The six patients with MAP less than or equal to
105 mmHg show an insignificant fall in episodes of symptomatic
hypotension per treatment on changing to hemofiltration. The
same holds true for those with hypertension. The number of
study subjects (N 15) in the hypertensive group increases the
strength of this lack of significant difference considerably.
An alternative way of analyzing this data takes into account
the clinical perception that certain patients are prone to have
symptomatic hypotension, whereas others appear to be resist-
ant to this ill effect of treatment. Figure 3 divides the study
population on the basis of the number of episodes of sympto-
matic hypotension per treatment during the control period on
hemodialysis. Ten patients who, on average, had one or less
episodes of symptomatic hypotension per hemodialysis treat-
ment are shown as group A (0.48 0.1 episodes per treatment)
to the left whereas the remaining 11 (Group B) with more than
one episode per treatment (2.1 0.2) appear in the bar graph to
Table 1. Comparative composition of the hemodialysis bath and
hemofiltration diluting fluid in mEq/liter.
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Fig. 2. The number of episodes of SHfor each treatment is shown. The
study subjects are divided into those with hypertension (mean arterial
pressure> 105 mmHg) and those who are normotensive. Hemodialysis
(HD) is compared with hemofiltration (HF). N represents the number of
patients in each group.
the right. Examining their response to hemofiltration shows that
for the three months of this experimental therapy, Group A had
a statistically significant increase in symptomatic hypotension
with hemofiltration, whereas Group B showed a significant
reduction in incidence.
Figure 4 plots episodes of symptomatic hypotension per
treatment for only the hypertensive patients. This group was
further subdivided into those who showed a statistically signif-
icant fall in MAP when control observations on hemodialysis
were compared with the values obtained in the third month on
hemoffitration, and those who showed either no change or an
increase in MAP over control values. Only the latter group (N
= 5), who showed no change or a worsening of their hyperten-
sion, had a significant improvement in their frequency of
symptomatic hypotension per treatment.
Mean pre- to post-treatment sodium levels in the plasma for
the entire patient group were no different than control measure-
ments (D-0 = 133 .6 to 130 .64 mEq/Liter) for the third
month ofhemofiltration (F-3 = 134 .5 to 132 1.4 mEq/Liter)
or in the third month of return to dialysis (D-3 = 132 .9 to 127
2.1 mEq/Liter). Table 2 compares the sodium and blood urea
nitrogen concentration of the plasma in study Groups A and B
prior to treatment and shows the pre- to post-treatment change
in concentration for these parameters obtained during the
control period on hemodialysis (D-0) and for the third month on
hemofiltration (F-3). None of the differences between study
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Fig. 3. The number of episodes of SN for each treatment is shown. The
study subjects are divided into Group A and B according to whether the
incidence of SH in the D-0 control period ws <I or >1. The incidence
of SH with HD is compared with HF.
Groups A and B achieved statistical significance. Actually the
change in both the concentrations of urea and sodium noted in
the D-0 control period for Group A (low incidence) were larger
than Group B, which is the reverse of what might be expected
if changes in plasma osmolality are to be correlated with
symptomatic hypotension. As expected, pretreatment values
for blood urea nitrogen were slightly higher for both study
Groups during the hemoffitration treatment period. Weight loss
during treatment for both study periods showed no difference
between Groups A and B. As altered body content of sodium
could be masked by parallel changes in body water, we exam-
ined the relationship between total body water as reflected by
body wt and pretreatment MAP. A least squares regression of
pretreatment MAP on wt gain between treatment days was
performed for the data pairs from the entire study population of
21 patients and for the A and B subsets of the population
discussed above. Table 3 gives the regression parameters for
these lines and their statistical significances. The correlation
coefficient values are very low (0.13 to 0.10) suggesting the lack
of any useful predictive relationship between these parameters
for a given treatment. The slopes for all three lines, however,
are highly significantly different from zero. The statistical
strength of the difference in slopes from zero stems from the
large number of data pairs (N) available for analysis. The
intercepts of the lines, that is, MAP with no gain in weight
between treatments, show group A (109 mmHg) to be very
significantly (P < 0.001) higher than group B (105 mmHg).
Table 4 shows temperature change with treatment for 17 of
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those who did not, failed to reveal any statistical differences.
Not shown are the results of the cold pressor test as all values
were within normal limits both on hemodialysis and hemofiltra-
tion. This finding is comparable to prior studies by others [5, 7]
in patients on hemodialysis,
Discussion
The present study tries to correlate the improved hemody-
namic stability noted during hemofiltration treatment with pre-
viously identified correlates of stability noted on studying the
response to hemodialysis alone; that is, hypertension afferent
limb barorefiex arc neuropathy and increase in body tempera-
ture [7, 8]. In examining the entire group, the mean arterial
pressure at dry weight, Table 3, was higher for those who had
fewer episodes of symptomatic hypotension (Group A) than for
those who had the higher frequency (Group B). When selecting
patients by the presence or absence of hypertension during
maintenance hemodialysis, we were not only unable to show a
parallel difference in the incidence of symptomatic hypotension
but were unable to correlate its change in incidence with
changes in pretreatment MAP. Further, the normotensive and
hypertensive patients showed an insignificant reduction in
symptomatic hypotension of equivalent degree (Fig. 3) and if
the study subject number had been marterially larger we might
well have been able to demonstrate a significant fall in both
groups. With reference to Figure 4, further analysis of only the
patients with hypertension showed that those with a fall in mean
arterial pressure, when mean values for the D-0 control period
were contrasted with the third month on hemofiltration, showed
the same incidence of symptomatic hypotension when moving
to hemofiltration. Even more at odds with previous work [5, 6,
7] is the observation in those patients who showed no change or
an increase in mean arterial pressure that there was a significant
reduction in the incidence of symptomatic hypotension on
moving to hemofiltration (Fig. 4). Lastly, with respect to the
correlation between the presence of hypertension and a high
frequency of symptomatic hypotension, is our observation that
mean arterial pressure in those patients showing the higher
frequency, Group B is lower than in Group A with the low
incidence. This finding is at odds with the work of Lilley et al in
which a positive not an inverse correlation was made in a very
similar patient population [7].
We were unable to document any change in the amyl nitrite
inhalation test with hemofiltration. Others have failed to corre-
late the incidence of symptomatic hypotension with baroreflex
arc dysfunction, however this latter work relied on valsalva
maneuver and venoconstrictor response rather than amyl
nitrite—induced hypotension as the test modality [12]. It should
be noted that the amyl nitrite inhalation study tests the
cardioregulatory element of the baro:eflex arc which has a
vasoregulatory component in addition [13]. We would not have
been able to identify a selective improvement of vasoregulation
with the present study protocol except as it might be reflected in
the lowering of MAP with hemofiltration. However, the corre-
lation in our study of a fall in incidence of symptomatic
hypotension with no change or an increase in MAP on switching
to hemofiltration, points away from a direct role of the auto-
nomic nervous system in this fall in incidence of symptomatic
hypotension. The lack of change noted in plasma dopamine
B-hydroxylase also supports this lack of correlation. Our data
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Fig. 4. The number of episodes of SHfor each treatment is shown. Only
those study subjects with MAP> 105 mmHg in the D-0 control period
were selected (N = 15). These subjects were further subdivided
according to whether MAP fell significantly (P C 0.05) or not with HF.
the 21 patients in which temperature recordings were complete
on all treatments with hemodialysis and hemofiltration. There
was a significant rise in temperature with both procedures, and
that noted for hemodialysis was significantly more than that
with hemofiltration. Figure 5 shows the temperature change
with treatment for study groups A and B. Changes in Group A
were no different than those for Group B, and neither showed a
significant difference in pre- to post-temperature on moving
from hemodialysis to hemofiltration.
Dopamine B-hydroxylase values (mean I snM) drawn
pretreatment for all patients showed no significant differences
between the control value on dialysis (D-0 = 37 7 lu) and that
after three months on hemofiltration (F-3 = 33 S Ju) or that
following return to three months of dialysis (D-3 = 36 6 lu)
plasma.
Not all patients consented to undergo autonomic nervous
system testing and hence only 13 complete studies are available
for analysis. Amyl nitrite inhalation studies and cold pressor
tests were conducted on three of the normotensive patients and
10 of those with hypertension. Studies were performed at the
conclusion of the control study month on hemodialysis and
repeated at the conclusion of the third month on hemofiltration.
Table 5 shows the results for the amyl nitrite test. All values of
the amyl nitrite inhalation test were markedly abnormal (<5
msec/mmHg) when compared with non-uremic control subjects
(17.4 4.1 msec/mmHg) [11] and remained so following three
months of treatment with hemofiltration. Dividing the popula-
tion into Group A vs. Group B (not shown), or normotensive
vs. hypertensive groups, or those who showed a fall in MAP vs.
Cardiovascular response to hemofiltration 905
Table 2. Sodium, BUN and body weight values for study groups A and B.
Treatment
period
Group A Group B
BUN,
mg/dliter
Sodium,
mEqlliter
Weight,
kg
BUN,
mg/dliter
Sodium,
mEqlliter
Weight,
kg
D-0
Pre
Pre-Post
F-3
Pre
Pre-Post
91 11
47 7
96 8
37 6
133 1.3
3.2 .98
132 1.5
0.52 .74
75.9 1.9
1.84 .3
73.3 2.7
2.70 .3
80 339 3
94 840 6
134 2.4
2.4 1.1
132 2.1
1.5 1.3
74.74 2.1
2.3 .2
73.6 2.4
2.30 .3
No statistically significant differences are noted either between group A and B values or for those within a study group between the D-0 and F-3
study periods.
Intercept,
Group Slope 1 SEM mmHg r P Slope N
All Patients 1.54 31 107 .12 <0.0001 1850
A 1.7 0.4 109* .13 <0.0001 938
B 1.3 0.4 105* .10 0.0035 912
* P < 0.0001.
Hemodialysis (Pre vs. Post) +0.99 0.72 N = 17 P < 0.001
Hemofiltration (Pre vs. Post) +0.36 0.58 N = 17 P = 0.02
does not, however, remove autonomic neuropathy from con-
sideration as an underlying abnormality in the end stage renal
failure patient that may contribute to vascular instability during
variations in intravascular volume. The lack of good quality
linear correlation between MAP and intertreatment wt gain is of
interest in this regard. One must argue that fluid wt gain
between treatments must either not be reflective of changes in
plasma volume or that plasma volume and MAP do not corre-
late well in this population. Previous work by ourselves and
others indicates that while plasma volume itself shows a poor
correlation with MAP in the chronic uremic patient, the ratio of
plasma volume to interstitial volume correlates very well indeed
[14, 15].
Maggiore et al [81 have presented evidence that routine
maintenance hemofiltration is associated with lower core body
temperature than hemodialysis, and that when experimental
manipulation reverses this temperature difference that hemody-
namic instability during treatment reverses in parallel with
fewer episodes of symptomatic hypotension for both
hemodialysis and hemofiltration. Our data does not contest that
hemodynamic stability may be improved by cooling of the
patient, but rather disputes that temperature is the causative
force that links fewer episodes of symptomatic hypotension
with hemofiltration when contrasted with dialysis. Recent work
from this group points up a reduction in complement activation
that occurs with reduced blood temperature in the extracorpo-
IAI IBI
____________
A' IB'I1
8 9 8 9
Patient group (N)
RR in Millise
Mean
c/MAP mmHg,
1 SEM
HD Post-HF
Normotensive (3)
Hypertensive
MAP, fall (5)
MAP, no change or increase (5)
3.50
2.16
2.07
.65
.45
.62
4.11 1.83
1.53 .18
2.63 1.3
No significant differences are present.
real circuit [16]. We and others have shown complement
activation to be strongly present with exposure of blood to
cuprophane membrane either in vivo or in vitro [17—201. While
clear proof of a causative link between symptomatic hypoten-
sion and complement activation is at present lacking, the study
of Hakim et al [21] showing a correlation between C3a levels
and signs and symptoms occurring during dialysis, as well as
Table 3. Regression line parameters.
MAP on weight gain, kg
POST- PR E
TEMP
Temperature response to
Treatment for groups A(1)
and 8(>1)
NS NS
Table 4. Temperature change with treatment in degrees farenheit,
Mean 1 SEM.
1.0 —
°F 0
n
—1.0
The difference in temperature rise between hemofiltration and
hemodialysis is significant (P = 0.03).
T
Hemodialysis Hemofiltration
Treatment
Fig. 5. The change in temperature is shown in degrees farenheit (F)for
study subject groups A and B during hemodialysis in the left panel. The
results for the same study subjects are shown in the right panel (A', B')
during hemofiltration.
Table 5. Amyl nitrite inhalation study.
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recent work [221 on the lower incidence of symptomatic hypo-
tension with reused cuprophane dialyzers (saline rinse formal-
dehyde storage protocol), taken in context with the report of
lower complement activation in these reused dialyzers [181, is
supportive of such a link. Studies of complement activation by
ourselves and others point up that the polysulfone membrane
used for hemofiltration in this study does not show significant
complement activation [23, 24]. Further investigation will be
necessary to determine if this difference in membrane proper-
ties underlies the lower incidence of symptomatic hypotension
in this study, or for that matter, in other studies comparing
symptoms and signs between hemodialysis and hemofiltration.
The identification that one subset of our study population shows
an increase in symptomatic hypotension on moving to
polysulfone membrane will have to be taken into account before
accepting this explanation.
The lack of difference in wt lost during treatment between
patients on hemodialysis and hemofiltration and, in particular,
where the patients are broken out by A and B study groups,
points away from a correlation between symptomatic hypoten-
sion and the amount of ultrafiltrate removed per treatment. A
difference in distribution between body spaces of this net loss of
total body water for hemofiltration and hemodialysis might
however be explanatory [151. The difference in composition of
the dialysis bath and diluting fluid bears comment. The net
osmolar flux rate is an important secondary determinant of
vascular volume in that vascular refilling rate is a function of
oncotic, osmotic, and hydrostatic transmembrane pressures at
the microvascular level [25, 26]. Sodium in the substitution fluid
(140 mEq/liter) of the present experiment was higher than that
used in dialysate (133 mEq/Liter). Sodium concentration of the
plasma water at the end of treatment then might be expected to
be higher with hemofiltration than with hemodialysis. That it is
not suggests greater recruitment of sodium—free water from the
intracellular space. Such an increase in extracellular water
might be expected to improve cardiovascular stability. That
study Group A showed an increase in symptomatic hypotension
with hemofiltration points away from the difference in net
osmolar flux as causative in the reduced incidence of sympto-
matic hypotension noted with hemofiltration. In addition, work
by Shaldon et al [27] points away from net sodium balance as
etiologic in this event. The use of acetate for both treatment
modalities, and its direct delivery into the blood path with
hemofiltration, points away from the cardiodepressant/vaso-
dilatory properties of this agent as explanatory of any differ-
ences noted between the two techniques.
In conclusion, the present experiments do not support the
previous empirical correlation put forward by Lilley et al [7]
between cardiovascular instability during hemodialysis treat-
ment (as manifest by the incidence of symptomatic hypoten-
sion) and hypertension. Furthermore, the incidence of sympto-
matic hypotension could be dissociated from afferent limb
baroreflex arc neuropathy, net body temperature change, and
alterations in net osmolar flux when treatment with hemofiltra-
tion was introduced. It is not readily apparent as to why our
results differ from Lilley et al [7], except as selection criteria for
the patients utilized were different and patient populations for
both our study (N = 21) and that of Lilley et al (N = 10) were
small. The degree of improvement in the amyl nitrite inhalation
study noted by Lilley et al was from a value of 1.2 0.6 to 5.1
1.6 msec/minHg. It should be noted that while these numbers
show statistical significance, the clinical meaning of the differ-
ence between them has yet to be established when normal
values in the nonuremic control population are 17.4 4
mmsec/mmHg. Lastly, while temperature variation with treat-
ment in our work did not correlate in the manner described by
Maggiore et a! [8] with the incidence of symptomatic hypoten-
sion, the study designs were sufficiently different to prevent
detailed comparison. As previously noted, correlation between
temperature elevation and clinical symptoms will require differ-
entiation between net calorie balance across the extracorporeal
blood circuit and other events that may result in alterations in
body temperature [281.
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